Aclarubicin is a new anthracycline antitumor antibiotic, which has strong antitumor activity against various transplanted animal tumors such as L310, P388, Ehlrich ascites carcinoma, Lewis lung cancer, S100 sarcoma, B16 melanoma, CDF8 and C3H breast cancer. This product can inhibit the biomacromolecule synthesis of cancer cells, especially the inhibition of RNA synthesis. This product has certain cardiotoxicity and bone marrow suppression effects on experimental animals, but the effects are reversible. This product has reproductive toxicity.

The drug can penetrate into cells, bind to chromosomes, and interfere with DNA and RNA synthesis and protein synthesis by inserting between DNA base pairs; at low concentrations, it can cleave DNA through topoisomerase II to destroy its structure; it is related to oxidation/reduction, producing cytotoxic compounds such as peroxides, active hydroxyl groups and hydrogen peroxide; it may also bind to lipids on cell membranes to affect multiple functions. Doxorubicin is active throughout the cell cycle, and has a significant anti-proliferative effect on rapidly proliferating tissues such as tumor tissues.

This product is a semi-synthetic anthracycline anticancer drug. It enters the cell nucleus and quickly embeds into the DNA base pairs, interfering with the transcription process, preventing mRNA synthesis, inhibiting DNA polymerase and DNA topoisomerase Ⅱ (Topoisomerase Ⅱ, Topo Ⅱ) activity, and interfering with DNA synthesis. Because this product interferes with DNA and mRNA synthesis at the same time, it blocks cells from entering the G1 phase in the cell proliferation cycle, interferes with tumor cell division, and inhibits tumor growth, so it has strong anticancer activity.

Docetaxel is a paclitaxel anti-tumor drug that exerts its anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function. Docetaxel can bind to free tubulin, promote tubulin assembly into stable microtubules, and inhibit its depolymerization, resulting in the production of microtubule bundles that have lost their normal function and the fixation of microtubules, thereby inhibiting cell mitosis. The binding of docetaxel to microtubules does not change the number of protofilaments, which is different from most spindle toxic drugs currently used in clinical practice.

Hydroxycamptothecin is a cell cycle-specific drug that mainly acts on the S phase. It has a targeted and selective inhibitory effect on DNA topoisomerase I, inhibiting TOPOI and thus inhibiting the replication and transcription of cancer cells. It has no obvious cross-resistance with other commonly used anticancer drugs.